Table 4 Outcome of stimulation in patients with clomiphene citrate-resistant polycystic ovary syndrome and comparison between HP-uFSH and r-FSH (* values are expressed as mean ± SD; ns = not significant)
| Â | Overall | HP-uFSH | rFSH | P |
|---|---|---|---|---|
N. of patients | 76 | 39 | 37 | Â |
N. of stimulation cycles | 76 | 39 | 37 | Â |
Total FSH dose (IU) * | 648 ± 498 | 833 ± 307 | 546 ± 346 | 0.002 |
Duration of follicular phase (days) * | 12.1 ± 3.9 | 11.9 ± 3.6 | 12.2 ± 3.7 | ns |
No. of preovulatory follicles ≥ 18 mm at hCG * | 2.0 ± 0.9 | 2.0 ± 0.8 | 2.0 ± 0.9 | ns |
No. of follicles 12–17 mm at hCG * | 4.2 ± 2.1 | 4.2 ± 2.0 | 4.1 ± 1.9 | ns |
Size of the dominant follicle at hCG (mm) * | 20.8 ± 1.8 | 20.8 ± 1.6 | 20.9 ± 1. 7 | ns |
Endometrial thickness at hCG (mm) * | 10.7 ± 2.0 | 10.9 ± 1.7 | 10.5 ± 1.9 | ns |
Monofollicular cycles (%) | 28 (36.8) | 13 (33.3) | 15 (40.5) | ns |
Bi/trifollicular cycles (%) | 12 (15.8) | 6 (15.4) | 6 (16.2) | ns |
Cancelled cycles (%) | 36 (47.4) | 20 (51.3) | 16 (43.2) | ns |
Deliveries | 11 | 4 | 7 | Â |
Delivery rate/started cycle (%) | 14.5 | 10.3 | 18.9 | ns |
Delivery rate/ovulatory cycle (%) | 27.5 | 21.1 | 33.3 | ns |